콘텐츠로 건너뛰기

SOLUTIONS
R&D
ABOUT US
- Overview
- History
- Partnership
- CI & BI
NEWS
CAREER

Menu

SOLUTIONS
R&D
ABOUT US
- Overview
- History
- Partnership
- CI & BI
NEWS
CAREER

Press Release

“AI and mRNA collaboration, a new paradigm”, said PharmCADD CEO

<View Original Article>

“AI and mRNA collaboration, a new paradigm”, said PharmCADD CEO 더 읽기"

PharmCADD held a research and recruiting seminar at University of North Carolina.

<View Original Article>

PharmCADD held a research and recruiting seminar at University of North Carolina. 더 읽기"

AI efficiently discovered reliable mRNA vaccine candidates

<View Original Article>

AI efficiently discovered reliable mRNA vaccine candidates 더 읽기"

PharmCADD built an mRNA specialized research team.

<View Original Article>

PharmCADD built an mRNA specialized research team. 더 읽기"

PharmCADD strategically collaborated with CNRS

<View Original Article>

PharmCADD strategically collaborated with CNRS 더 읽기"

The mayor, Hyung-Jun Park of Busan proposed vitalization of local human resource and knowledge leveraged by the collaboration among local governance, academy and industry

<View Original Article>

The mayor, Hyung-Jun Park of Busan proposed vitalization of local human resource and knowledge leveraged by the collaboration among local governance, academy and industry 더 읽기"

The capabilities of PharmCADD’s vaccine platform are being verified through approval of a phase I/IIa trial for mRNA COVID-19 vaccine

<View Original Article>

The capabilities of PharmCADD’s vaccine platform are being verified through approval of a phase I/IIa trial for mRNA COVID-19 vaccine 더 읽기"

PharmCADD’s mRNA Vaccine design platform PharmVAC™: Eyegene Corona 19 vaccine candidate ‘EG-COVID’ mRNA sequence design

<View Original Article>

PharmCADD’s mRNA Vaccine design platform PharmVAC™: Eyegene Corona 19 vaccine candidate ‘EG-COVID’ mRNA sequence design 더 읽기"

PharmCADD signed partnership for preparing KOSDAQ listing in next year with Korea Investment & Securities

<View Original Article>

PharmCADD signed partnership for preparing KOSDAQ listing in next year with Korea Investment & Securities 더 읽기"

PharmCADD signed a collaborative research contract for innovative new drug development with NeuroVenti for Autism.

<View Original Article>

PharmCADD signed a collaborative research contract for innovative new drug development with NeuroVenti for Autism. 더 읽기"

← 이전 1 … 6 7 8 … 11 다음 →

Headquarters

Address : 224, Engineering Building 7, Sinseon-Ro 365, Namgu, Busan 48548, Republic of Korea
Call : 82-51-747-5681 | Fax : 82-51-747-5682

Seoul Office

Address : 1735, 280, Gwangpyeong-ro, Gangnam-gu, Seoul, Republic of Korea
Call : 82-2-564-5688 | Fax : 82-2-564-5685

E-Mail : [email protected]
Call : 82-51-747-5681

Linkedin-in Youtube

© 2021 PharmCADD. All Rights Reserved.